Pharming Announces US FDA Acceptance Of Snda For Lower Doses Of Joenja

Sept 25 (Reuters) - Pharming Group N.V. PHAR.AS:

• PHARMING ANNOUNCES U.S. FDA ACCEPTANCE AND PRIORITY REVIEW OF SNDA FOR LOWER DOSES OF JOENJA® TO TREAT CHILDREN WITH APDS

• PHARMING GROUP N.V. - APPLICATION GRANTED PRIORITY REVIEW WITH PDUFA DATE JANUARY 30, 2027

• PHARMING GROUP N.V. - FDA ACCEPTS PHARMING'S SNDA FOR LOWER DOSES OF JOENJA

• PHARMING GROUP N.V. - PDUFA TARGET ACTION DATE OF JANUARY 30, 2027

Further company coverage: PHAR.AS